Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Keratoconus, Unstable: early-phase trial registry

1 of 3 indexed Keratoconus, Unstable trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count

Keratoconus, Unstable: 3 US clinical trials tracked, 1 recruiting.

Keratoconus, Unstable is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Eye Specialists of Indiana, running 1 of these trials.

Enrollment posture brief

Registry condition keratoconus-unstable

OPEN 1 | RECR 33% | LATE 1 | EARLY 2 | RANK #5209 | SPON 1

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Keratoconus, Unstable (this)33%
Open-enrollment share among volume-matched conditions near Keratoconus, Unstable

Keratoconus, Unstable lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Keratoconus, Unstable on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Keratoconus, Unstable is recruiting below its size-band peers.

    1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 21Phase 41

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 4 1

Named interventions

Most-linked intervention names on Keratoconus, Unstable records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

PXL 330 Platinum device/Riboflavin Combination
1 trials
Prednisolone Acetate Drug
1 trials
PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution Combination
1 trials
Dextenza Drug
1 trials

US sites by state

Facility locations filed on Keratoconus, Unstable trials. A trial with sites in several states counts in each.

Oregon 1 trials
New York 1 trials
Indiana 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Keratoconus, Unstable page

3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Keratoconus, Unstable condition card totals 3 registered trials; most-linked intervention PXL 330 Platinum device/Riboflavin; top US site state Oregon. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.